会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS
    • 生物医学标记之间的多模式关联的鉴定
    • WO2012046191A3
    • 2012-06-07
    • PCT/IB2011054366
    • 2011-10-04
    • KONINKL PHILIPS ELECTRONICS NVCOLD SPRING HARBOR LABBANERJEE NILANJANAJANEVSKI ANGELKAMALAKARAN SITHARTHANVARADAN VINAYDIMITROVA NEVENKALUCITO ROBERT
    • BANERJEE NILANJANAJANEVSKI ANGELKAMALAKARAN SITHARTHANVARADAN VINAYDIMITROVA NEVENKALUCITO ROBERT
    • G06F19/12
    • G06F19/20G06F19/12G06F19/18
    • The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.
    • 本发明涉及一种用于识别生物医学标记之间的多模式关联的方法,其允许确定网络节点和/或高排名网络成员或其组合,指示具有医疗状况的诊断,预后或预测值, 特别是卵巢癌。 本发明进一步涉及与受试者对癌症疗法的响应性的高度可能性相关联的生物医学标记物或生物医学标记物组,其中所述生物医学标记物或生物医学标记物组包括至少1种, 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,8,19,20或所有选自PKMYT1,SKIL,RAB8A,HIRIP3, CTNNB1,NGFR,ZCCHC11,LSP1,CD200,PAX8,CYBRD1,HOXC11,TCEAL1,FZD10,FZD1,BBS4,IRS2,TLX3,TSPAN2,TXN和CFLAR。 此外,提供了用于检测,诊断,分级,监测或预测医疗状况或用于检测,诊断,监测或预测受试者针对所述医疗状况,特别是卵巢癌的疗法的响应性的测定,作为 以及用于分类包括医疗决策支持系统的对象的相应方法。